Trials / Completed
CompletedNCT01159769
Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 215 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®) | Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2010-07-09
- Last updated
- 2012-04-03
- Results posted
- 2012-04-03
Source: ClinicalTrials.gov record NCT01159769. Inclusion in this directory is not an endorsement.